Tenax Therapeutics TENX Stock
Tenax Therapeutics Price Chart
Tenax Therapeutics TENX Financial and Trading Overview
| Tenax Therapeutics stock price | 10.77 USD |
| Previous Close | 11.87 USD |
| Open | 11.8 USD |
| Bid | 8.66 USD x 200 |
| Ask | 14.96 USD x 200 |
| Day's Range | 11.5 - 12.1 USD |
| 52 Week Range | 5.34 - 18.38 USD |
| Volume | 1.65M USD |
| Avg. Volume | 538.13K USD |
| Market Cap | 317.51M USD |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.41 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 29.71 USD |
TENX Valuation Measures
| Enterprise Value | 169.4M USD |
| Trailing P/E | N/A |
| Forward P/E | -8.489362 |
| PEG Ratio (5 yr expected) | 1.44 |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 5.231643 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | N/A |
Trading Information
Tenax Therapeutics Stock Price History
| Beta (5Y Monthly) | N/A |
| 52-Week Change | 95.23% |
| S&P500 52-Week Change | 27.69% |
| 52 Week High | 18.38 USD |
| 52 Week Low | 5.34 USD |
| 50-Day Moving Average | 13.46 USD |
| 200-Day Moving Average | 10.68 USD |
TENX Share Statistics
| Avg. Volume (3 month) | 538.13K USD |
| Avg. Daily Volume (10-Days) | 481.5K USD |
| Shares Outstanding | 26.53M |
| Float | 10.61M |
| Short Ratio | 1.15 |
| % Held by Insiders | 0.12% |
| % Held by Institutions | 84.20% |
| Shares Short | 775.85K |
| Short % of Float | 2.95% |
| Short % of Shares Outstanding | 2.93% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:80 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | March 31, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -32.74% |
| Return on Equity (ttm) | -51.70% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | N/A |
| Net Income Avi to Common (ttm) | -57907000 USD |
| Diluted EPS (ttm) | -1.41 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 118.76M USD |
| Total Cash Per Share (mrq) | 4.89 USD |
| Total Debt (mrq) | 0 USD |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 14.515 |
| Book Value Per Share (mrq) | 2.288 |
Cash Flow Statement
| Operating Cash Flow (ttm) | N/A |
| Levered Free Cash Flow (ttm) | N/A |
Profile of Tenax Therapeutics
| Country | United States |
| State | NC |
| City | Chapel Hill |
| Address | 101 Glen Lennox Drive |
| ZIP | 27517 |
| Phone | 919 855 2100 |
| Website | https://www.tenaxthera.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 14 |
Tenax Therapeutics, Inc., a development-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States. It develops TNX-101, TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension in heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is headquartered in Chapel Hill, North Carolina.
Q&A For Tenax Therapeutics Stock
What is a current TENX stock price?
Tenax Therapeutics TENX stock price today per share is 10.77 USD.
How to purchase Tenax Therapeutics stock?
You can buy TENX shares on the Tech Market Small exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Tenax Therapeutics?
The stock symbol or ticker of Tenax Therapeutics is TENX.
Which industry does the Tenax Therapeutics company belong to?
The Tenax Therapeutics industry is Biotechnology.
How many shares does Tenax Therapeutics have in circulation?
The max supply of Tenax Therapeutics shares is 26.53M.
What is Tenax Therapeutics Price to Earnings Ratio (PE Ratio)?
Tenax Therapeutics PE Ratio is now.
What was Tenax Therapeutics earnings per share over the trailing 12 months (TTM)?
Tenax Therapeutics EPS is -1.41 USD over the trailing 12 months.
Which sector does the Tenax Therapeutics company belong to?
The Tenax Therapeutics sector is Healthcare.
Tenax Therapeutics TENX included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| US Tech Composite IXIC | 26853.98 USD — |
-0.89
|
8.32B USD — | 26769.16 USD — | 27130.88 USD — | — - | 8.32B USD — |
| US Tech Composite Total Return XCMP | 33104.2 USD — |
-0.89
|
— — | 32999.64 USD — | 33445.55 USD — | — - | — — |
| US Tech Capital Market Composite RCMP | 148.96 USD — |
-1.84
|
— — | 148.23 USD — | 151.02 USD — | — - | — — |
| US Tech Health Care IXHC | 1133.51 USD — |
+1.54
|
— — | 1113.35 USD — | 1133.95 USD — | — - | — — |
- {{ link.label }} {{link}}